Zhifei Zu

578 total citations
8 papers, 461 citations indexed

About

Zhifei Zu is a scholar working on Molecular Biology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhifei Zu has authored 8 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Reproductive Medicine and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhifei Zu's work include Ovarian cancer diagnosis and treatment (5 papers), Renal cell carcinoma treatment (2 papers) and Renal and related cancers (2 papers). Zhifei Zu is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Renal cell carcinoma treatment (2 papers) and Renal and related cancers (2 papers). Zhifei Zu collaborates with scholars based in United States and Taiwan. Zhifei Zu's co-authors include Kwong‐Kwok Wong, Yvonne T.M. Tsang, David M. Gershenson, Samuel C. Mok, Anaís Malpica, Michael T. Deavers, Judith K. Wolf, Karen H. Lu, Charlotte C. Sun and Celestine S. Tung and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Cancer Research.

In The Last Decade

Zhifei Zu

8 papers receiving 459 citations

Peers

Zhifei Zu

RM

MB

ONCOL

CR

PFM

Jun Naniwa Japan

Moito Iijima Japan

Tayyebeh M. Nazeran Canada

PD Pharoah United Kingdom

Agnieszka Timorek Poland

Laura M S Seeber Netherlands

AL Tesdale United Kingdom

Hang Tran United States

Miyuki Kurai Japan

Sherman Lau Canada

Jun Naniwa Japan

Zhifei Zu

158 ×0.6

RM

223 ×0.9

MB

114 ×1.0

ONCOL

53 ×0.6

CR

79 ×0.9

PFM

Citations per year, relative to Zhifei Zu Zhifei Zu (= 1×) peers Jun Naniwa

Countries citing papers authored by Zhifei Zu

Since Specialization

Citations

This map shows the geographic impact of Zhifei Zu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhifei Zu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhifei Zu more than expected).

Fields of papers citing papers by Zhifei Zu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhifei Zu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhifei Zu. The network helps show where Zhifei Zu may publish in the future.

Co-authorship network of co-authors of Zhifei Zu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhifei Zu. A scholar is included among the top collaborators of Zhifei Zu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhifei Zu. Zhifei Zu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Crane, Erin K., Yvonne T.M. Tsang, Lisa K. Mullany, et al.. (2015). Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS ONE. 10(8). e0135101–e0135101. 39 indexed citations

2.

Song, Huijuan, Zhifei Zu, Yvonne T.M. Tsang, et al.. (2013). PAX2 Expression in Ovarian Cancer. International Journal of Molecular Sciences. 14(3). 6090–6105. 22 indexed citations

3.

Zu, Zhifei, et al.. (2013). Abstract 3474: GDF15 as a serum marker of cisplatin response in ovarian cancer cells.. Cancer Research. 73(8_Supplement). 3474–3474. 1 indexed citations

4.

King, Erin R., Zhifei Zu, Yvonne T.M. Tsang, et al.. (2011). The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecologic Oncology. 123(1). 13–18. 48 indexed citations

5.

King, Erin R., Celestine S. Tung, Yvonne T.M. Tsang, et al.. (2011). The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. The American Journal of Surgical Pathology. 35(6). 904–912. 86 indexed citations

6.

Wong, Kwong‐Kwok, Yvonne T.M. Tsang, Michael T. Deavers, et al.. (2010). BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. American Journal Of Pathology. 177(4). 1611–1617. 160 indexed citations

7.

Tung, Celestine S., Samuel C. Mok, Yvonne T.M. Tsang, et al.. (2009). PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Modern Pathology. 22(9). 1243–1250. 75 indexed citations

8.

Du, Min, Leticia Sansores-García, Zhifei Zu, & Kenneth Wu. (1998). Cloning and Expression Analysis of a Novel Salicylate Suppressible Gene, Hs-CUL-3, a Member of Cullin/Cdc53 Family. Journal of Biological Chemistry. 273(38). 24289–24292. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact